Please use this identifier to cite or link to this item:
|Title:||Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand|
Thailand Ministry of Public Health
National Health Security Office
Thai AIDS Society
The HIV Netherlands Australia Thailand Research Collaboration
Khon Kaen University
|Keywords:||Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology;Medicine|
|Citation:||AIDS Research and Therapy. Vol.12, No.1 (2015)|
|Abstract:||© Manosuthi et al.; licensee BioMed Central. New evidence has emerged regarding when to commence antiretroviral therapy (ART), optimal treatment regimens, management of HIV co-infection with opportunistic infections, and management of ART failure. The 2014 guidelines were developed by the collaborations of the Department of Disease Control, Ministry of Public Health (MOPH) and the Thai AIDS Society (TAS). One of the major changes in the guidelines included recommending to initiating ART irrespective of CD4 cell count. However, it is with an emphasis that commencing HAART at CD4 cell count above 500 cell/mm<sup>3</sup> is for public health, in term of preventing HIV transmission and personal benefit. In tuberculosis co-infected patients with CD4 cell counts ≤50 cells/mm<sup>3</sup> or with CD4 cell counts >50 cells/mm<sup>3</sup> who have severe clinical disease, ART should be initiated within 2 weeks of starting tuberculosis treatment. The preferred initial ART regimen in treatment naïve patients is efavirenz combined with tenofovir and emtricitabine or lamivudine. Plasma HIV viral load assessment should be done twice a year until achieving undetectable results; and will then be monitored once a year. CD4 cell count should be monitored every 6 months until CD4 cell count ≥350 cells/mm<sup>3</sup> and with plasma HIV viral load <50 copies/mL; then it should be monitored once a year afterward. HIV drug resistance genotypic test is indicated when plasma HIV viral load >1,000 copies/mL while on ART. Ritonavir-boosted lopinavir or atazanavir in combination with optimized two nucleoside-analogue reverse transcriptase inhibitors is recommended after initial ART regimen failure. Long-term ART-related safety monitoring has also been included in the guidelines.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.